MitoQ dosage and evidence

What is MitoQ?

How does MitoQ work?

MitoQ is the active head of coenzyme Q10 (ubiquinone) bolted to a positively charged carrier (triphenylphosphonium). Mitochondria carry a strong negative charge inside, so the carrier piles up there, several hundred times more than elsewhere. Normal antioxidants spread all over the body. MitoQ gathers right where mitochondria make the damaging molecule superoxide. It is not a stand-in for CoQ10, though. The carrier gets in the way, so it cannot pass electrons along the energy chain the way CoQ10 does.

What have studies in people found about MitoQ?

One study in healthy older adults, with a dummy pill for comparison, showed better blood vessel function. There is some scattered smaller work. No data in people on lifespan or real health events.

• In 20 healthy older adults, taking MitoQ and a dummy pill for six weeks each, in turn, improved how well the blood vessel lining relaxed. A blood marker of oxidative damage also fell.
• It measured how blood vessels behave, not blood pressure over time, heart attacks, strokes or deaths.
• The study is small, so the size of the effect is uncertain and should be read with caution.
• No human study has looked at lifespan, healthy years, thinking or any hard health event.
• Separately, in mice tested at several labs, it made no clear difference to lifespan.

What this does not tell you: The blood vessel result is a real test in people. It is also one small study measuring a stand-in marker. Better blood vessel lining predicts heart risk. It is not the same as fewer heart attacks, and nobody has tested that here. The mouse lifespan test is the direct test of the ageing claim, and it was a no. Do not read the blood vessel finding as support for the longevity claim. They are different questions with different answers.

What do people who took MitoQ report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• The amount most often discussed is 10 mg daily, with 5 mg mentioned for younger and healthier people and 20 mg for those who consider themselves under more oxidative stress. Higher amounts are described as giving progressively less in return.
• The clearest split in the discussion is by starting health. Younger users without a condition repeatedly report no subjective difference at all over weeks, several saying coffee is more noticeable, while people with an existing condition describe energy changes. Both groups post in the same threads and neither position is fringe.
• Some describe a stretch of feeling flat or worse for several weeks before anything changed, which they interpret optimistically. Overstimulation and anxiety at higher intakes are described by others.
• Cost is the most frequent complaint and the most common reason given for reducing the amount taken or stopping, with people comparing it unfavourably against ordinary coenzyme Q10 and cheaper alternatives.
• One long running account from someone with a mitochondrial condition describes an initial change over the first couple of months that then settled to something they considered comparable to high dose conventional coenzyme Q10 rather than clearly different from it.
• An important caveat about this source: company representatives take part in these threads and answer dosing questions directly, so the figures circulating there are not independent of the seller.

Sources: Long running MitoQ product discussion threads on LongeCity, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.

The state of the research

The evidence, in charts

The studies we cite

• Study in people2018
  Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults

  Blood vessel function improved, in a study of twenty people. Healthy older adults whose arteries were already responding poorly took MitoQ for six weeks and a dummy pill for six weeks, in turn, without knowing the order. The lining of their arteries relaxed better after MitoQ. A blood marker of oxidative damage also fell. This is the strongest human result the compound has. It measures how a blood vessel behaves, not whether anybody lived longer or better.

  A randomised placebo-controlled trial in healthy older adults reporting improved vascular function after chronic MitoQ supplementation. This is the strongest human result for the compound, it is small, and the endpoint is a physiological measure rather than a clinical event.

  PMID 29661838 Hypertension
• Animal study2024
  Targeting mitochondrial dysfunction using methylene blue or mitoquinone to improve skeletal aging

  In animals. This work looked at whether drugs aimed at mitochondria, MitoQ and methylene blue, improve bones as they age. Bone is a tissue where ageing mitochondria may play a part that can be tested on its own.

  Animal work examining whether mitochondria-targeted agents improve skeletal ageing, covering both mitoquinone and methylene blue. Included because bone is a tissue where mitochondrial ageing has a plausible and separately testable role.

  PMID 38535998 Aging